Accessory cells for β-cell transplantation.
Despite recent advances, insulin therapy remains a treatment, not a cure, for diabetes mellitus with persistent risk of glycaemic alterations and life-threatening complications. Restoration of the endogenous β-cell mass through regeneration or transplantation offers an attractive alternative. Unfortunately, signals that drive β-cell regeneration remain enigmatic and β-cell replacement therapy still faces major hurdles that prevent its widespread application. Co-transplantation of accessory non-islet cells with islet cells has been shown to improve the outcome of experimental islet transplantation. This review will highlight current travails in β-cell therapy and focuses on the potential benefits of accessory cells for islet transplantation in diabetes.
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.|Division of Pediatric Endocrinology, Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.|Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium.
W
W
Staels
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
S
S
De Groef
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
Y
Y
Heremans
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
V
V
Coppens
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
N
N
Van Gassen
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
G
G
Leuckx
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
M
M
Van de Casteele
Department Hematology Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
I
I
Van Riet
Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
A
A
Luttun
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
H
H
Heimberg
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.|Department of Endocrinology, UZ Brussel, Brussels, Belgium.|Department of Endocrinology, ASZ Aalst, Aalst, Belgium.
N
N
De Leu
D000818:Animals; D049109:Cell Proliferation; D002469:Cell Separation / Q000639:trends; D002478:Cells, Cultured; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D066026:Endothelial Progenitor Cells / Q000166:cytology / Q000276:immunology / Q000473:pathology / Q000637:transplantation; D006084:Graft Rejection / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007108:Immune Tolerance; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D016381:Islets of Langerhans Transplantation / Q000009:adverse effects / Q000276:immunology; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects / Q000639:trends; D009432:Neural Crest / Q000166:cytology / Q000276:immunology / Q000473:pathology / Q000637:transplantation; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000639:trends; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000276:immunology / Q000473:pathology / Q000637:transplantation; D014182:Transplantation, Autologous / Q000009:adverse effects / Q000639:trends; D016042:Transplantation, Heterotopic / Q000009:adverse effects / Q000639:trends; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000639:trends
accessory cells; diabetes; pancreas; transplantation; β cell